As shown in Fig. 5, compared to HCV-infected patients with HBV reactivation, non-HCV infected patients with HBV reactivation who were treated with immunosuppressive agents/anti-cancer drugs or underwent BMT had significantly higher IL-1β levels than did those without HBV reactivation. This evidence concerns the gene IL1B and cancer.